Journal Article > ResearchFull Text
Southern African Journal of HIV medicine. 2019 November 8; Volume 20 (Issue 1); 1030.; DOI:10.4102/sajhivmed.v20i1.1030
Govender NP, Meintjes GA, Mangena PM, Nel J, Potgieter S, et al.
Southern African Journal of HIV medicine. 2019 November 8; Volume 20 (Issue 1); 1030.; DOI:10.4102/sajhivmed.v20i1.1030
Journal Article > ResearchFull Text
PLOS One. 2021 April 26; Volume 16 (Issue 4); e0250195.; DOI:10.1371/journal.pone.0250195
Deiss R, Loreti C, Gutierrez AG, Filipe E, Tatia M, et al.
PLOS One. 2021 April 26; Volume 16 (Issue 4); e0250195.; DOI:10.1371/journal.pone.0250195
BACKGROUND
Cryptococcal meningitis is a leading cause of HIV-related mortality in sub-Saharan Africa, however, screening for cryptococcal antigenemia has not been universally implemented. As a result, data concerning cryptococcal meningitis and antigenemia are sparse, and in Mozambique, the prevalence of both are unknown.
METHODS
We performed a retrospective analysis of routinely collected data from a point-of-care cryptococcal antigen screening program at a public hospital in Maputo, Mozambique. HIV-positive patients admitted to the emergency department underwent CD4 count testing; those with pre-defined abnormal vital signs or CD4 count ≤ 200 cells/μL received cryptococcal antigen testing and lumbar punctures if indicated. Patients with CM were admitted to the hospital and treated with liposomal amphotericin B and flucytosine; their 12-week outcomes were ascertained through review of medical records or telephone contact by program staff made in the routine course of service delivery.
RESULTS
Among 1,795 patients screened for cryptococcal antigenemia between March 2018-March 2019, 134 (7.5%) were positive. Of patients with cryptococcal antigenemia, 96 (71.6%) were diagnosed with CM, representing 5.4% of all screened patients. Treatment outcomes were available for 87 CM patients: 24 patients (27.6%) died during induction treatment and 63 (72.4%) survived until discharge; of these, 38 (60.3%) remained in care, 9 (14.3%) died, and 16 (25.3%) were lost-to follow-up at 12 weeks.
CONCLUSIONS
We found a high prevalence of cryptococcal antigenemia and meningitis among patients screened at an emergency department in Maputo, Mozambique. High mortality during and after induction therapy demonstrate missed opportunities for earlier detection of cryptococcal antigenemia, even as point-of-care screening and rapid assessment in an emergency room offer potential to improve outcomes.
Cryptococcal meningitis is a leading cause of HIV-related mortality in sub-Saharan Africa, however, screening for cryptococcal antigenemia has not been universally implemented. As a result, data concerning cryptococcal meningitis and antigenemia are sparse, and in Mozambique, the prevalence of both are unknown.
METHODS
We performed a retrospective analysis of routinely collected data from a point-of-care cryptococcal antigen screening program at a public hospital in Maputo, Mozambique. HIV-positive patients admitted to the emergency department underwent CD4 count testing; those with pre-defined abnormal vital signs or CD4 count ≤ 200 cells/μL received cryptococcal antigen testing and lumbar punctures if indicated. Patients with CM were admitted to the hospital and treated with liposomal amphotericin B and flucytosine; their 12-week outcomes were ascertained through review of medical records or telephone contact by program staff made in the routine course of service delivery.
RESULTS
Among 1,795 patients screened for cryptococcal antigenemia between March 2018-March 2019, 134 (7.5%) were positive. Of patients with cryptococcal antigenemia, 96 (71.6%) were diagnosed with CM, representing 5.4% of all screened patients. Treatment outcomes were available for 87 CM patients: 24 patients (27.6%) died during induction treatment and 63 (72.4%) survived until discharge; of these, 38 (60.3%) remained in care, 9 (14.3%) died, and 16 (25.3%) were lost-to follow-up at 12 weeks.
CONCLUSIONS
We found a high prevalence of cryptococcal antigenemia and meningitis among patients screened at an emergency department in Maputo, Mozambique. High mortality during and after induction therapy demonstrate missed opportunities for earlier detection of cryptococcal antigenemia, even as point-of-care screening and rapid assessment in an emergency room offer potential to improve outcomes.
Journal Article > ResearchFull Text
Int J Infect Dis. 2020 June 1; Volume 95; 459-461.; DOI:10.1016/j.ijid.2020.02.057
Shroufi A, Govender NP, Meintjes GA, Black JM, Nel J, et al.
Int J Infect Dis. 2020 June 1; Volume 95; 459-461.; DOI:10.1016/j.ijid.2020.02.057
BACKGROUND
Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority occurring in Sub Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in hospital by as much as 40% compared to the standard of care, yet due to market failure quality assured flucytosine remains unregistered and largely inaccessible throughout Africa.
METHODS
The recently established South African flucytosine clinical access programme is an attempt to address market failure which led to a lack of public-sector access to flucytosine for cryptococcal meningitis, by making the medicine freely available to tertiary hospitals in South Africa.
RESULTS
Between November 2018 and September 2019, 327 CM patients received flucytosine through this programme, with efforts to support sustainable national scale up presently ongoing. We describe why this programme was needed, its catalytic potential, what is still required to ensure widespread access to flucytosine, and observation from this experience that may have wider relevance.
CONCLUSIONS
The South African Flucytosine Access Programme illustrates how access programmes may be one part of the solution to addressing the vicious cycle of perceived low demand, limiting manufacturer interest in specific product markets.
Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority occurring in Sub Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in hospital by as much as 40% compared to the standard of care, yet due to market failure quality assured flucytosine remains unregistered and largely inaccessible throughout Africa.
METHODS
The recently established South African flucytosine clinical access programme is an attempt to address market failure which led to a lack of public-sector access to flucytosine for cryptococcal meningitis, by making the medicine freely available to tertiary hospitals in South Africa.
RESULTS
Between November 2018 and September 2019, 327 CM patients received flucytosine through this programme, with efforts to support sustainable national scale up presently ongoing. We describe why this programme was needed, its catalytic potential, what is still required to ensure widespread access to flucytosine, and observation from this experience that may have wider relevance.
CONCLUSIONS
The South African Flucytosine Access Programme illustrates how access programmes may be one part of the solution to addressing the vicious cycle of perceived low demand, limiting manufacturer interest in specific product markets.
Journal Article > ResearchAbstract Only
Lancet Infect Dis. 2022 June 21; Volume s1473-3099 (Issue 22); 00234-1.; DOI: 10.1016/S1473-3099(22)00234-1
Mashau RC, Meiring ST, Quan VC, Nel J, Greene GS, et al.
Lancet Infect Dis. 2022 June 21; Volume s1473-3099 (Issue 22); 00234-1.; DOI: 10.1016/S1473-3099(22)00234-1
BACKGROUND
Although flucytosine is a key component of WHO-recommended induction treatment for HIV-associated cryptococcal meningitis, this antifungal agent is not widely available in low-income and middle-income countries due to limited production and cost. In 2018, a national flucytosine access programme was initiated in South Africa. We aimed to determine the effectiveness of flucytosine-containing induction regimens in routine care to motivate for the urgent registration of flucytosine and its inclusion in treatment guidelines.
METHODS
In this cross-sectional study, we compared outcomes of adults aged 18 years and older with incident laboratory-confirmed cryptococcal meningitis treated with or without flucytosine-containing regimens at 19 sentinel hospitals in South Africa. A case of cryptococcosis was defined as illness in an adult with: (1) positive cerebrospinal fluid (CSF) India ink microscopy; (2) a positive CSF cryptococcal antigen test; or (3) culture of Cryptococcus neoformans or Cryptococcus gattii from CSF or any other specimen. We excluded patients without a case report form, those with an unknown or negative HIV serology result, those with a recurrent episode, and those who did not receive antifungal treatment in hospital. We assessed cumulative in-hospital mortality at 14 days and 30 days and calculated the overall crude in-hospital case-fatality ratio. We used random-effects logistic regression to examine the association between treatment group and in-hospital mortality.
FINDINGS
From July 1, 2018, to March 31, 2020, 10 668 individuals were diagnosed with laboratory-confirmed cryptococcal meningitis, 7787 cases diagnosed at non-enhanced surveillance sites and 567 cases from eight enhanced surveillance sites with no access to flucytosine were excluded. Of 2314 adults with a first episode of cryptococcosis diagnosed at 19 facilities with access to flucytosine, 1996 had a case report form and of these, 1539 received induction antifungal treatment and were confirmed HIV-seropositive first-episode cases. Of 1539 patients who received antifungal therapy, 596 (38·7%) individuals received a flucytosine-containing regimen and 943 (61·3%) received another regimen. The median age was 36 years (IQR 32-43) and 906 (58·9%) participants were male and 633 (41·1%) were female. The crude in-hospital case-fatality ratio was 23·9% (95% CI 20·0-27·0; 143 of 596) in those treated with flucytosine-containing regimens and 37·2% (95% CI 34·0-40·0; 351 of 943) in those treated with other regimens. Patients admitted to non-academic hospitals (adjusted odds ratio [aOR] 1·95 [95% CI 1·53-2·48]; p<0·0001) and those who were antiretroviral treatment-experienced (aOR 1·30 [1·02-1·67]; p=0·033) were more likely to receive flucytosine. After adjusting for relevant confounders, flucytosine treatment was associated with a 53% reduction in mortality (aOR 0·47 [95% CI 0·35-0·64]; p<0·0001). Among survivors, the median length of hospital admission in the flucytosine group was 11 days (IQR 8-15) versus 17 days (13-21) in the comparison group (p=0·0010).
INTERPRETATION
In-hospital mortality among patients treated with a flucytosine-containing regimen was comparable to reduced mortality reported in patients receiving a flucytosine-containing regimen in a recent multicentre African clinical trial. Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit.
FUNDING
National Institute for Communicable Diseases, a Division of the National Health Laboratory Service.
Although flucytosine is a key component of WHO-recommended induction treatment for HIV-associated cryptococcal meningitis, this antifungal agent is not widely available in low-income and middle-income countries due to limited production and cost. In 2018, a national flucytosine access programme was initiated in South Africa. We aimed to determine the effectiveness of flucytosine-containing induction regimens in routine care to motivate for the urgent registration of flucytosine and its inclusion in treatment guidelines.
METHODS
In this cross-sectional study, we compared outcomes of adults aged 18 years and older with incident laboratory-confirmed cryptococcal meningitis treated with or without flucytosine-containing regimens at 19 sentinel hospitals in South Africa. A case of cryptococcosis was defined as illness in an adult with: (1) positive cerebrospinal fluid (CSF) India ink microscopy; (2) a positive CSF cryptococcal antigen test; or (3) culture of Cryptococcus neoformans or Cryptococcus gattii from CSF or any other specimen. We excluded patients without a case report form, those with an unknown or negative HIV serology result, those with a recurrent episode, and those who did not receive antifungal treatment in hospital. We assessed cumulative in-hospital mortality at 14 days and 30 days and calculated the overall crude in-hospital case-fatality ratio. We used random-effects logistic regression to examine the association between treatment group and in-hospital mortality.
FINDINGS
From July 1, 2018, to March 31, 2020, 10 668 individuals were diagnosed with laboratory-confirmed cryptococcal meningitis, 7787 cases diagnosed at non-enhanced surveillance sites and 567 cases from eight enhanced surveillance sites with no access to flucytosine were excluded. Of 2314 adults with a first episode of cryptococcosis diagnosed at 19 facilities with access to flucytosine, 1996 had a case report form and of these, 1539 received induction antifungal treatment and were confirmed HIV-seropositive first-episode cases. Of 1539 patients who received antifungal therapy, 596 (38·7%) individuals received a flucytosine-containing regimen and 943 (61·3%) received another regimen. The median age was 36 years (IQR 32-43) and 906 (58·9%) participants were male and 633 (41·1%) were female. The crude in-hospital case-fatality ratio was 23·9% (95% CI 20·0-27·0; 143 of 596) in those treated with flucytosine-containing regimens and 37·2% (95% CI 34·0-40·0; 351 of 943) in those treated with other regimens. Patients admitted to non-academic hospitals (adjusted odds ratio [aOR] 1·95 [95% CI 1·53-2·48]; p<0·0001) and those who were antiretroviral treatment-experienced (aOR 1·30 [1·02-1·67]; p=0·033) were more likely to receive flucytosine. After adjusting for relevant confounders, flucytosine treatment was associated with a 53% reduction in mortality (aOR 0·47 [95% CI 0·35-0·64]; p<0·0001). Among survivors, the median length of hospital admission in the flucytosine group was 11 days (IQR 8-15) versus 17 days (13-21) in the comparison group (p=0·0010).
INTERPRETATION
In-hospital mortality among patients treated with a flucytosine-containing regimen was comparable to reduced mortality reported in patients receiving a flucytosine-containing regimen in a recent multicentre African clinical trial. Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit.
FUNDING
National Institute for Communicable Diseases, a Division of the National Health Laboratory Service.
Journal Article > LetterFull Text
Lancet. 2000 December 16; Volume 356 (Issue 9247); 2102.; DOI:10.1016/S0140-6736(05)74314-2
Perez-Casas C, Chirac P, Berman D, Ford NP
Lancet. 2000 December 16; Volume 356 (Issue 9247); 2102.; DOI:10.1016/S0140-6736(05)74314-2
Journal Article > ResearchFull Text
Public Health Action. 2023 August 1; Volume 13 (Issue 2(Suppl1)); 7-12.; DOI:10.5588/pha.23.0005
Ditondo P, Luemba A, Chuy RI, Mucinya G, Ade S
Public Health Action. 2023 August 1; Volume 13 (Issue 2(Suppl1)); 7-12.; DOI:10.5588/pha.23.0005
CONTEXTE
Médecins Sans Frontières Belgique a mis en place des diagnostics au point de service (DPS) pour le dépistage précoce d’un VIH avancé, et en présence de celle-ci, d’une TB et d’une cryptococcose, dans six centres de santé (Kasai, St Ambroise, St Joseph, Libondi, Lisanga et Kimia) à Kinshasa, République Démocratique du Congo (RDC).
OBJECTIF
Documenter leur contribution dans le diagnostic de ces affections.
MÉTHODE
Ceci est une étude transversale rétrospective sur des adolescents et adultes VIH-positif, admis avec suspicion d’un VIH avancé. Une comparaison 2 ans avant et 2 ans après installation des DPS a été réalisée.
RÉSULTATS
Au total, 745 et 887 patients étaient retenus respectivement avant et après l’installation des DPS. L’âge moyen était de 39,7 ans (déviation standard [DS] 12,04); 66% (n = 1 077) étaient des femmes. Les patients avec CD4 dosés étaient passés de 40,3% (n = 300) à 64,4% (n = 573) (P < 0,001). Après l’installation des DPS, ils variaient entre 47,8% (Lisanga) et 97,1% (Kasai). La proportion d’infection à VIH avancé était comparable (n = 158, 52,7% vs. n = 288, 50,3%; P = 0,779). Chez les patients avec un VIH avancé, la TB était dépistée chez 28,5% (n = 82), dont 41,5% (n = 34) de confirmation; la cryptococcose était dépistée chez 24,7% (n = 71), dont 9,9% (n = 7) de confirmation. Des disparités entre les centres étaient observés.
CONCLUSION
Les DPS ont augmenté l’accès des patients au dosage des CD4 et au diagnostic d’un VIH avancé dans les six centres dans la RDC. Cependant des actions sont requises pour améliorer cette performance, y compris le dépistage de la TB et de la cryptococcose.
Médecins Sans Frontières Belgique a mis en place des diagnostics au point de service (DPS) pour le dépistage précoce d’un VIH avancé, et en présence de celle-ci, d’une TB et d’une cryptococcose, dans six centres de santé (Kasai, St Ambroise, St Joseph, Libondi, Lisanga et Kimia) à Kinshasa, République Démocratique du Congo (RDC).
OBJECTIF
Documenter leur contribution dans le diagnostic de ces affections.
MÉTHODE
Ceci est une étude transversale rétrospective sur des adolescents et adultes VIH-positif, admis avec suspicion d’un VIH avancé. Une comparaison 2 ans avant et 2 ans après installation des DPS a été réalisée.
RÉSULTATS
Au total, 745 et 887 patients étaient retenus respectivement avant et après l’installation des DPS. L’âge moyen était de 39,7 ans (déviation standard [DS] 12,04); 66% (n = 1 077) étaient des femmes. Les patients avec CD4 dosés étaient passés de 40,3% (n = 300) à 64,4% (n = 573) (P < 0,001). Après l’installation des DPS, ils variaient entre 47,8% (Lisanga) et 97,1% (Kasai). La proportion d’infection à VIH avancé était comparable (n = 158, 52,7% vs. n = 288, 50,3%; P = 0,779). Chez les patients avec un VIH avancé, la TB était dépistée chez 28,5% (n = 82), dont 41,5% (n = 34) de confirmation; la cryptococcose était dépistée chez 24,7% (n = 71), dont 9,9% (n = 7) de confirmation. Des disparités entre les centres étaient observés.
CONCLUSION
Les DPS ont augmenté l’accès des patients au dosage des CD4 et au diagnostic d’un VIH avancé dans les six centres dans la RDC. Cependant des actions sont requises pour améliorer cette performance, y compris le dépistage de la TB et de la cryptococcose.